The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma [0.03%]
抗体药物偶联物在弥漫性大B细胞淋巴瘤有效治疗中的潜力
Gulrayz Ahmed,Mehdi Hamadani,Taha Al-Juhaishi
Gulrayz Ahmed
Introduction: Antibody-drug conjugates (ADCs) are a rapidly evolving class of anti-cancer drugs with a significant impact on management of hematological malignancies including diffuse large B-cell lymphoma (DLBCL). ADCs c...
Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment? [0.03%]
难治性弥漫大B细胞淋巴瘤二线治疗中应考虑将CAR-T细胞疗法作为标准治疗吗？
Lucia Perez-Lamas,Jose Sandoval-Sus,Julio C Chavez
Lucia Perez-Lamas
Introduction: CAR-T therapy has transformed the treatment landscape for relapsed/refractory diffuse large B-cell lymphomas (DLBCL). Areas covered: ...
Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer [0.03%]
基因治疗在非肌层浸润性膀胱癌治疗中的应用展望
Alexis R Steinmetz,Behzad Jazayeri,Morgan Pierce et al.
Alexis R Steinmetz et al.
Introduction: Approximately 75% of bladder cancer cases are non-muscle invasive at diagnosis. Drug development for non-muscle invasive bladder cancer (NMIBC) has historically lagged behind that of other malignancies. No t...
Clinical updates in mesenchymal stromal cell therapy for osteoarthritis treatment [0.03%]
间充质基质细胞治疗骨关节炎的临床进展更新
Gun-Il Im
Gun-Il Im
Introduction: Osteoarthritis (OA) is a common chronic musculoskeletal disease with heterogeneous clinical manifestations and variable responses to different treatments. Unfortunately, there is no effective disease modifyi...
Benralizumab: from tissue distribution to eosinophilic cytotoxicity up to potential immunoregulation [0.03%]
本拉利珠单抗：从组织分布到嗜酸性细胞毒性再到潜在的免疫调节作用
Alessandra Vultaggio,Laura Bergantini,Claudia Crimi et al.
Alessandra Vultaggio et al.
Introduction: Benralizumab, a monoclonal IgG antibody, has emerged as a key therapeutic agent in severe asthma by specifically targeting eosinophils, pivotal cells that drive inflammation and tissue damage. Over the past ...
An evaluation of sugemalimab for the treatment of relapsed or refractory extranodal natural killer T-cell lymphoma [0.03%]
评估舒格利单抗治疗复发或难治性结外自然杀伤细胞/T细胞淋巴瘤的效果
Yingfang Feng,Xia Liu,Jingwei Yu et al.
Yingfang Feng et al.
Introduction: Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive subtype arising from natural killer or cytotoxic T-cells, predominantly affecting the nasal cavity and pa...
Adeleh Taei,Fatemeh-Sadat Sajadi,Sarvenaz Salahi et al.
Adeleh Taei et al.
Introduction: The remarkable ability of human pluripotent stem cells (hPSCs) to differentiate into specialized cells of the human body emphasizes their immense potential in treating various diseases. Advances in hPSC tech...
Advances in CD19-targeting CAR-T cell therapies for multiple myeloma [0.03%]
针对多发性骨髓瘤的CD19靶向CAR-T细胞疗法进展
Maximilian J Steinhardt,Hermann Einsele,Johannes M Waldschmidt
Maximilian J Steinhardt
Introduction: Emerging evidence suggests that, while CD19 is primarily expressed on immature B-cell precursors, it is also present on drug-resistant plasma cells that have been postulated to function as multiple myeloma (...
An up-to-date review of emerging biologic therapies for hypercholesterolemia [0.03%]
高胆固醇血症的新型生物治疗药物进展及评述
Brian Tomlinson
Brian Tomlinson
Introduction: Hypercholesterolemia and other lipid disorders are major causes of atherosclerotic cardiovascular disease (ASCVD). Statins have been the mainstay of lipid-lowering therapy for many years, but they may not be...
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project [0.03%]
VALORE项目中的意大利队列研究：怀孕前、怀孕期间和怀孕后的生物药使用轨迹
Sara Lopes,Michela Servadio,Andrea Spini et al.
Sara Lopes et al.
Background: Monitoring biologic drug therapy during pregnancy in women with immune-mediated inflammatory diseases (IMIDs) is crucial to ensure treatments align with evidence-based practices. ...